Key facts
- Notable investors include CAS Star, YuanBio Venture Capital, Hankang Capital, Shiyu Capital, Suzhou Equity Investment Fund Management — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Puhe Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Puhe Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Puhe Pharmaceutical
Operator of a pharmaceutical company intended to develop innovative small-molecule drugs. The company offers a pipeline of clinical-stage drugs focused on targeted therapies, enabling patients to get proper treatment of their diseases.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- puhebiopharma.com/
- Ownership
- Privately Held (backing)
Puhe Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Puhe Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Puhe Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.